PMCB
PharmaCyte Biotech, Inc.
$0.7079
+1.13%
$7.5M
No data for this timeframe.
Vol
Market Cap$7.5M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$122.6K
Inst. Activity0 buys / 2 sells
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. NV·CIK 0001157075·Prev Close $0.7000
Recent Activity
Mar 31, 2026
Insider
Abecassis Michael M sold 119,170 shares
Director @ $0.00 ($0.00)
Mar 31, 2026
Insider
SCHECHTER JONATHAN sold 119,170 shares
Director @ $0.00 ($0.00)
Mar 31, 2026
Insider
WEINSTEIN ROBERT sold 119,170 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — TRIM
314 shares ($227.00)
Inst.
MORGAN STANLEY — NEAR_EXIT
2 shares ($2.00)
Mar 16, 2026
earnings_calendar
PMCB Q3 2026 Earnings Scheduled — 2026-03-16
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 8, 2021 | HC Wainwright & Co. | INITIATE | Neutral |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $68.1K | ADD |
| VANGUARD GROUP INC | $54.2K | TRIM |
| BANK OF AMERICA CORP | $227.00 | TRIM |
| MORGAN STANLEY | $2.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Abecassis Michael | A | $0.00 |
| Mar 31, 2026 | SCHECHTER JONATHAN | A | $0.00 |
| Mar 31, 2026 | WEINSTEIN ROBERT | A | $0.00 |
| Mar 31, 2026 | WALKER WAYNE | A | $0.00 |
4 institutional holders with $122.6K total value (169,271 shares) as of 2025-Q4. Top holders: RENAISSANCE, VANGUARD, BANK. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 94,036 | $68.1K | 55.6% | ADD +60.6% |
| 2 | VANGUARD GROUP INC | 74,919 | $54.2K | 44.3% | TRIM -61.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 314 | $227.00 | 0.2% | TRIM -41.6% |
| 4 | MORGAN STANLEY | 2 | $2.00 | 0.0% | NEAR_EXIT -77.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 538 | 314 | -41.6% | $227.00 | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 9 | 2 | -77.8% | $2.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 49,800 | 80,000 | +60.6% | $77.6K | 2025-Q3 |
| VANGUARD GROUP INC | TRIM | 194,447 | 74,919 | -61.5% | $72.7K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 22,592 | 1,323 | -94.1% | $1.3K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 1 | 9 | +800.0% | $10.00 | 2025-Q3 |
| UBS Group AG | ADD | 11,916 | 22,592 | +89.6% | $24.6K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 73 | 542 | +642.5% | $591.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,874 | 11,916 | +535.9% | $14.9K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 2 | 1 | -50.0% | $2.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 13,900 | — | $21.5K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 8,354 | 1,874 | -77.6% | $2.9K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 3 | 2 | -33.3% | $5.00 | 2024-Q3 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Abecassis Michael M | Director | A | 119,170 | $0.00 | $0.00 |
| Mar 31, 2026 | SCHECHTER JONATHAN | Director | A | 119,170 | $0.00 | $0.00 |
| Mar 31, 2026 | WEINSTEIN ROBERT | Director | A | 119,170 | $0.00 | $0.00 |
| Mar 31, 2026 | WALKER WAYNE REMELL | Director | A | 119,170 | $0.00 | $0.00 |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2021): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2022-10-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-04-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 8, 2021 | HC Wainwright & Co. | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2022 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Nov 1, 2022 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Mar 16, 2026
earnings_calendar
PMCB Q3 2026 Earnings Scheduled — 2026-03-16